Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal

Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.

Source link